248 related articles for article (PubMed ID: 36819518)
1. A multi-center retrospective study on the efficacy and safety of regorafenib
Yan T; Huang C; Peng C; Duan X; Ji D; Duan Y; Zhang W; Zhao H; Gao K; Yang X; Zhang L; Cheng J; de Castria TB; Pocha C; Tsilimigras DI; Wu T; Su G; Li Y; Yu L; Lu Y
Ann Transl Med; 2023 Jan; 11(2):109. PubMed ID: 36819518
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
[TBL] [Abstract][Full Text] [Related]
3. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.
Xu Y; Fu S; Shang K; Zeng J; Mao Y
Front Oncol; 2022; 12():958869. PubMed ID: 36176403
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice.
Liu K; Wu J; Xu Y; Li D; Huang S; Mao Y
Onco Targets Ther; 2022; 15():1079-1094. PubMed ID: 36212725
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Huang J; Guo Y; Huang W; Hong X; Quan Y; Lin L; Zhou J; Liang L; Zhang Y; Zhou J; Cai M; Zhu K
J Hepatocell Carcinoma; 2022; 9():157-170. PubMed ID: 35300208
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice.
Bi H; Pei J; Ma K; Zhang Y; Aprile G; Moris D; Méndez-Sánchez N; Samant H; Sun X; Xia F
J Gastrointest Oncol; 2024 Feb; 15(1):368-376. PubMed ID: 38482245
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Yang X; Deng H; Sun Y; Zhang Y; Lu Y; Xu G; Huang X
J Hepatocell Carcinoma; 2023; 10():303-313. PubMed ID: 36874252
[TBL] [Abstract][Full Text] [Related]
9. Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy.
Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
J Gastrointest Oncol; 2022 Jun; 13(3):1248-1254. PubMed ID: 35837179
[TBL] [Abstract][Full Text] [Related]
10. Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma.
Li J; Jia Y; Shao C; Li Y; Song J
Ther Clin Risk Manag; 2023; 19():329-339. PubMed ID: 37041973
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy combination with regorafenib for refractory hepatocellular carcinoma: A real-world study.
Tu X; Yang J; Zheng Y; Liang C; Tao Q; Tang X; Liu Z; Jiang L; He Z; Xie F; Zheng Y
Int Immunopharmacol; 2022 Dec; 113(Pt B):109401. PubMed ID: 36395672
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.
Qiao L; He W; Wang G; Chen H; Huang F; Zhang B; Qiu Y; Liu S; Huang Z; Yuan Y; Qiu J; Yuan Y; Li B
Cancer Med; 2024 May; 13(9):e7236. PubMed ID: 38716585
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy.
Xu B; Lu D; Liu K; Lv W; Xiao J; Zhang X; Zhang Z; Chai J; Wang L
Drug Des Devel Ther; 2023; 17():507-518. PubMed ID: 36814894
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
[TBL] [Abstract][Full Text] [Related]
17. Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting.
Falette-Puisieux M; Nault JC; Bouattour M; Lequoy M; Amaddeo G; Decaens T; Di Fiore F; Manfredi S; Merle P; Baron A; Locher C; Pellat A; Coriat R
Ther Adv Med Oncol; 2023; 15():17588359231189425. PubMed ID: 37547443
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance.
Zou X; Xu Q; You R; Yin G
J Hepatocell Carcinoma; 2023; 10():267-279. PubMed ID: 36815093
[TBL] [Abstract][Full Text] [Related]
19. Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib.
Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
J Gastrointest Oncol; 2022 Aug; 13(4):1907-1914. PubMed ID: 36092351
[TBL] [Abstract][Full Text] [Related]
20. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience.
Luo L; Xiao Y; Zhu G; Huang A; Song S; Wang T; Ge X; Xie J; Deng W; Hu Z; Wen W; Mei H; Wan R; Shan R
Front Oncol; 2022; 12():1004652. PubMed ID: 36237309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]